{"id":988525,"date":"2026-08-03T10:23:25","date_gmt":"2026-08-03T14:23:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/"},"modified":"2026-08-03T10:23:25","modified_gmt":"2026-08-03T14:23:25","slug":"ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/","title":{"rendered":"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue"},"content":{"rendered":"<p>        <!--.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nGE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFollowing the introduction of Invenia\u2122 ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to supplemental screening for women with dense breasts<\/p>\n<\/li>\n<li>\nABUS StreamVue\u2122* is a zero-footprint, browser-based reading solution designed to enable remote exam review from virtually anywhere across enterprise imaging networks and high-volume breast centers<\/p>\n<\/li>\n<\/ul>\n<p>CHICAGO&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGE HealthCare today announced the launch of Invenia\u2122 ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue\u2122, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, expanding its breast imaging portfolio with solutions designed to support supplemental screening for women with dense breasts and provide more flexible enterprise-wide exam review. Together, these new solutions aim to help breast imaging programs standardize 3D ultrasound acquisition, support remote reading, and simplify deployment across multi-site networks.<\/p>\n<p>\nStudies conducted in the U.S. and Europe show 40% of women have dense breasts<sup>1<\/sup>, these women have a 4 to 6 times higher risk of developing breast cancer.<sup>2<\/sup> Dense breasts can make cancers harder to detect on mammography, and may delay diagnosis.<sup>3,4,5<\/sup> Research has shown that mammography may miss one-third of cancers in dense breasts, underscoring the need for supplemental screening options for these patients.<sup>6<\/sup> According to results from the Breast Screening: Risk Adaptive Imaging for Density study, ABUS demonstrated higher acceptance and a more positive patient experience compared to other contrast-enhanced techniques.<sup>7<\/sup><\/p>\n<p>\n\u201cInvenia ABUS Prime builds on our commitment to advancing supplemental breast screening for women with dense breasts,\u201d said Karley Yoder, CEO, Ultrasound Solutions, Advanced Imaging Solutions, GE HealthCare. \u201cAs breast imaging networks look to scale across sites, Invenia ABUS Prime can help deliver streamlined workflows, reproducible imaging, with features designed to support both patient comfort and clinician efficiency.\u201d<\/p>\n<p>\nWhen used alongside mammography, Invenia ABUS Prime supports earlier cancer detection.<sup>8<\/sup> Across growing breast imaging networks, the system helps support standardized exams, more efficient workflows and operational consistency, particularly in multi-site imaging environments. Invenia ABUS Prime features:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\ncSound\u2122 Imageformer with AI-enabled tools including Scan Quality Assessment and Auto Nipple Detection\u2014powered by Verisound\u2122 AI\u2014developed to help deliver consistent, reproducible, high-quality scans and greater clinical confidence<\/p>\n<\/li>\n<li>\nA Fast Scan tool that increases scan speed by up to 40%, along with a new-generation Reverse Curve\u2122 transducer and selectable compression levels intended to enhance patient comfort and offer a more personalized patient experience<sup>9<\/sup><\/li>\n<li>\nAI-supported reading powered by QVCAD\u2122 is designed to streamline review.<sup>10<\/sup> AI Assistant powered by QVCAD has demonstrated a 33% reduction in reading time<sup>11<\/sup> and up to 93% sensitivity for lesion detection<sup>12<\/sup><\/li>\n<\/ul>\n<p>\nABUS StreamVue is a zero-footprint, browser-based reading solution built to standardize ABUS exam review with remote access and adaptable licensing intended to simplify installation, maintenance and growth for enterprise imaging environments. Candelis, Inc., a leading provider of innovative and cost-effective solutions to hospitals and imaging centers, is collaborating with GE HealthCare to deliver ABUS StreamVue technology in combination with Invenia ABUS. Together with Invenia ABUS Prime, this technology aims to facilitate faster reads, remote reading and easier comparisons across sites, while assisting IT teams in managing ultrasound systems more simply across the enterprise.<\/p>\n<p>\n\u201cABUS StreamVue extends the value of our ABUS platform with a flexible reading experience for enterprise imaging environments,\u201d said Russ Behler, Global Product Director, LOGIQ Ultrasound, GE HealthCare. \u201cThis solution supports remote review, more standardized presentation, and simpler deployment across care settings.\u201d<\/p>\n<p>\nAmong the first U.S. installations of Invenia ABUS Prime is in Los Angeles at BeSound, which offers a modern breast imaging experience to expand access to supplemental breast cancer screening. BeSound is also planning a mobile screening unit to bring imaging services closer to patients.<\/p>\n<p>\n\u201cAt BeSound, our mission is to make supplemental breast screening more accessible and more convenient for the women who need it,\u201d said Bailey Renger, Founder and CEO<b>, <\/b>BeSound. \u201cWith Invenia ABUS Prime, we hope to expand access to advanced breast imaging in a way that is patient-centered and meets women where they are.\u201d<\/p>\n<p>\nInvenia ABUS Prime is U.S. FDA Premarket approved and CE Marked. Availability is subject to local regulatory approvals and may vary by country. ABUS StreamVue is U.S. FDA 510(k) cleared and CE Marked. For more information on Invenia ABUS Prime and ABUS StreamVue, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fen%2Fproducts%2Fultrasound%2Fbreast-ultrasound%2Finvenia-abus&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.gehealthcare.com%2Fen%2Fproducts%2Fultrasound%2Fbreast-ultrasound%2Finvenia-abus&amp;index=1&amp;md5=8391bfd118edaa98d7cff865fc0398ce\">https:\/\/www.gehealthcare.com\/en\/products\/ultrasound\/breast-ultrasound\/invenia-abus<\/a>.<\/p>\n<p><i>*Powered by Candelis\u2122.<\/i><\/p>\n<p><b>About GE HealthCare Technologies Inc.<\/b><\/p>\n<p>\nGE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world\u2019s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.<\/p>\n<p>\nGE HealthCare is proud to be among <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Ffortune.com%252Franking%252Fworlds-most-admired-companies%252F%26data%3D05%257C02%257CJulie.Allison%2540gehealthcare.com%257C1d4ac6d8980f475655fe08deed8a7e29%257C9a309606d6ec4188a28a298812b4bbbf%257C0%257C0%257C639209376294222987%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DBcByDJx9qh9w7APzuw5UFeVgthVqjF63Ig6fmFeWDrk%253D%26reserved%3D0&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=2026+Fortune+World%26%238217%3Bs+Most+Admired+Companies%26%238482%3B.&amp;index=2&amp;md5=acf0e644a279cf1e7163d82256a7aeaf\">2026 Fortune World\u2019s Most Admired Companies\u2122.<\/a><\/p>\n<p>\nFollow us on<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fgehealthcare%26data%3D05%257C02%257CJulie.Allison%2540gehealthcare.com%257C1d4ac6d8980f475655fe08deed8a7e29%257C9a309606d6ec4188a28a298812b4bbbf%257C0%257C0%257C639209376294263839%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DtCDncAl1WKFhKv52ZPPVjxMq7s30XXoqaP75A0CWCAY%253D%26reserved%3D0&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=14b4148be5a3048361e25f2058b23b1c\"> LinkedIn<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.facebook.com%252FGEHealthCare%252F%26data%3D05%257C02%257CJulie.Allison%2540gehealthcare.com%257C1d4ac6d8980f475655fe08deed8a7e29%257C9a309606d6ec4188a28a298812b4bbbf%257C0%257C0%257C639209376294286342%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3D0yV9Cr%252Fktfsq2YW22aR7BksSFyoE%252F%252Fu5Z11jJkTfIbI%253D%26reserved%3D0&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=5069d41cfa06c1745b7be37363e3d6bf\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam10.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.instagram.com%252Fgehealthcare%252F%26data%3D05%257C02%257CJulie.Allison%2540gehealthcare.com%257C1d4ac6d8980f475655fe08deed8a7e29%257C9a309606d6ec4188a28a298812b4bbbf%257C0%257C0%257C639209376294308811%257CUnknown%257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%253D%253D%257C0%257C%257C%257C%26sdata%3DDApZoSYMxpalGIYECDj8aetMJNzV%252FsiaE5pgr8LOTi8%253D%26reserved%3D0&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=9828f94f6cb44c3862bc0c294deed9f0\">Instagram<\/a>, or visit our website for our <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Fabout%2Fnewsroom&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=latest+news&amp;index=6&amp;md5=e89176fc67923bc71e6606e9f2376cee\">latest news<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gehealthcare.com%2Finsights%3FshowPopup%3Dfalse&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=perspectives&amp;index=7&amp;md5=eb87c581fd95f95341bc4f59b6c5a1d2\">perspectives<\/a>.<\/p>\n<p><sup>1<\/sup> Pisano et al. NEJM 2005; 353: 1773.<\/p>\n<p><sup>2<\/sup> Boyd NF et al. NEJM 2007; 356: 227-36.<\/p>\n<p><sup>3<\/sup> Engmann NJ, et al, JAMA Oncol. 2017;3(9):1228-1236<\/p>\n<p><sup>4<\/sup> Mandelson et al. J Natl Cancer Inst 2000; 92:1081-1087.<\/p>\n<p><sup>5<\/sup> Tagliafico, Massimo Calabrese et al, Journal of Clinical Oncology 2016 34:16, 1882-188.<\/p>\n<p><sup>6<\/sup> \u00a0Mandelson et al. J Natl Cancer Inst 2000; 92:1081-1087.<\/p>\n<p><sup>7<\/sup> Allajbeu et.al., Acceptance, experience, and feedback for supplemental screening in dense breasts among women participating in the BRAID trial. Insights into Imaging, (2026) 17:14 <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1186%2Fs13244-025-02170-8.&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1186%2Fs13244-025-02170-8.&amp;index=8&amp;md5=94ab495bdea041cb0cd8f5b6269b8a21\">https:\/\/doi.org\/10.1186\/s13244-025-02170-8.<\/a><\/p>\n<p><sup>8<\/sup> The Lancet; May 2025; <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140&amp;index=9&amp;md5=3c5b695fea9180345cea4109f9603ec7\">https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140<\/a>\u20116736(25)00582\u20113\/fulltext.<\/p>\n<p><sup>9<\/sup> Compared to Invenia\u2122 ABUS 2.0.<\/p>\n<p><sup>10<\/sup> QVCAD is a trademark of QView Medical, Inc.<\/p>\n<p><sup>11<\/sup> Performance and Reading Time of Automated Breast US with or without Computer-Aided Detection. <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpubs.rsna.org%2Fdoi%2F10.1148%2Fradiol.2019181816&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=https%3A%2F%2Fpubs.rsna.org%2Fdoi%2F10.1148%2Fradiol.2019181816&amp;index=10&amp;md5=a5c7c5ba872dbc6fc5d0ff2b97fc26f2\">https:\/\/pubs.rsna.org\/doi\/10.1148\/radiol.2019181816<\/a>.<\/p>\n<p><sup>12<\/sup> Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women with Dense Breast Tissue (Yulei Jiang) Read more: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ajronline.org%2Fdoi%2F10.2214%2FAJR.18.19516&amp;esheet=54580309&amp;newsitemid=20260803008444&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ajronline.org%2Fdoi%2F10.2214%2FAJR.18.19516&amp;index=11&amp;md5=72e03ea3e9c1366cdc4d8c6d198ddf43\">https:\/\/www.ajronline.org\/doi\/10.2214\/AJR.18.19516<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260803008444\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260803008444\/en\/<\/a><\/span><\/p>\n<p><b>GE HealthCare Media Contact:<br \/>\n<\/b><br \/>Eric Tatro<br \/>\n<br \/>M +1 312 459 6140<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:eric.tatro@gehealthcare.com\">eric.tatro@gehealthcare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Illinois United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Women Oncology General Health Health FDA Medical Devices Health Technology Consumer<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue Following the introduction of Invenia\u2122 ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to supplemental screening for women with dense breasts ABUS StreamVue\u2122* is a zero-footprint, browser-based reading solution designed to enable remote exam review from virtually anywhere across enterprise imaging networks and high-volume breast centers CHICAGO&#8211;(BUSINESS WIRE)&#8211; GE HealthCare today announced the launch of Invenia\u2122 ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue\u2122, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, expanding its breast imaging &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-988525","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue Following the introduction of Invenia\u2122 ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to supplemental screening for women with dense breasts ABUS StreamVue\u2122* is a zero-footprint, browser-based reading solution designed to enable remote exam review from virtually anywhere across enterprise imaging networks and high-volume breast centers CHICAGO&#8211;(BUSINESS WIRE)&#8211; GE HealthCare today announced the launch of Invenia\u2122 ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue\u2122, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, expanding its breast imaging &hellip; Continue reading &quot;GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T14:23:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue\",\"datePublished\":\"2026-08-03T14:23:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/\"},\"wordCount\":1067,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/\",\"name\":\"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-08-03T14:23:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/","og_locale":"en_US","og_type":"article","og_title":"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue - Market Newsdesk","og_description":"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue Following the introduction of Invenia\u2122 ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles marks one of the first in the U.S., expanding access to supplemental screening for women with dense breasts ABUS StreamVue\u2122* is a zero-footprint, browser-based reading solution designed to enable remote exam review from virtually anywhere across enterprise imaging networks and high-volume breast centers CHICAGO&#8211;(BUSINESS WIRE)&#8211; GE HealthCare today announced the launch of Invenia\u2122 ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue\u2122, a redesigned enterprise viewer that recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, expanding its breast imaging &hellip; Continue reading \"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-03T14:23:25+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue","datePublished":"2026-08-03T14:23:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/"},"wordCount":1067,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/","name":"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-08-03T14:23:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260803008444r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ge-healthcare-expands-breast-imaging-portfolio-with-invenia-abus-prime-and-launch-of-abus-streamvue\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=988525"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/988525\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=988525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=988525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=988525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}